An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
Expert Opin Pharmacother
; 20(13): 1551-1561, 2019 Sep.
Article
in En
| MEDLINE
| ID: mdl-31328968
ABSTRACT
Introduction:
Brigatinib is a second-line inhibitor for the treatment of rearranged anaplastic lymphoma kinase (ALK) in lung cancer patients which has significant activity against brain metastases. This tyrosine kinase inhibitor (TKI) overcomes a wide range of ALK mutations which confer therapeutic resistance and is increasingly applied in first-line therapy due to improved benefit for patients compared to crizotinib, the current standard of care. Areas covered The authors review the development and characteristics of brigatinib and discuss the optimal clinical use and sequence of the application of ALK inhibitors in patients progressing under therapy. Expert opinion ALK-rearranged NSCLC can be treated with a broad range of approved and novel inhibitors at various stages of therapy, including the second-line therapeutic brigatinib. Besides this TKI, the second-line ALK inhibitors alectinib and ceritinib, as well as the third-line lorlatinib are approved for the treatment of ALK-positive NSCLC patients. The main challenge is to find sequences and combinations of ALK inhibitors which provide the best benefit for the patients.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organophosphorus Compounds
/
Pyrimidines
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Expert Opin Pharmacother
Journal subject:
FARMACOLOGIA
Year:
2019
Document type:
Article
Affiliation country:
Austria